Jung Eun Choi

Jung Eun Choi

Auto-generated profile, based on publicly available information

Jung Eun Choi

Department of Surgery, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2023 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JCJung Eun Choi
Jung Eun Choi
ZKZisun Kim
Zisun Kim
IPIn-Chul Park
In-Chul Park
EPEunhwa Park
Eunhwa Park
SLSae Byul Lee
Sae Byul Lee
TSThe Korean Breast Cancer Society
The Korean Breast Cancer Society
Choi JE, et al. J Breast Cancer. 2023 Jun;26:e27. https://doi.org/10.4048/jbc.2023.26.e27

29 June 2022 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
MKMinchong Kim
Minchong Kim
MPMin Hui Park
Min Hui Park
JCJung Eun Choi
Jung Eun Choi
SKSu Hwan Kang
Su Hwan Kang
YBYoung Kyung Bae
Young Kyung Bae
Kim MC, et al. J Breast Cancer. 2022 Jun;25:e31. https://doi.org/10.4048/jbc.2022.25.e31

1 June 2018 in Tumor Biology
Verified
Journal Article
Open access
HKHee Jung Kwon
Hee Jung Kwon
JCJung Eun Choi
Jung Eun Choi
YBYoung Kyung Bae
Young Kyung Bae
Interleukin-13 receptor alpha 2 is one of the subunits of transmembrane receptor for interleukin-13. The aim of this study was to investigate the prognostic value of interleukin-13 receptor alpha 2 expression in invasive breast cancer. Interleukin-13 receptor alpha 2 expressions were assessed by immunohistochemistry in tissue microarrays of 1283 invasive breast cancer samples, and associations between these expressions and clinicopathological variables and clinical outcomes were investigated. Interleukin-13 receptor alpha 2 expression was observed in 138 (10.8%) samples, and found to be associated with positive estrogen receptor (p < 0.001) and progesterone receptor (p < 0.001) and with the luminal subtype (p < 0.001). No significant association was found between interleukin-13 receptor alpha 2 expression and other clinicopathological variables including age, tumor size, lymph node metastasis, histologic types, histologic grade, HER2 status, Ki-67 labeling index, or tumor-infiltrating lymphocytes levels. Patients with interleukin-13 receptor alpha 2 expression tended to have poorer disease-free survival, but the difference was not statistically significant (p = 0.069). Subgroup analysis showed luminal breast cancer patients positive for interleukin-13 receptor alpha 2 expression had significantly poorer disease-free survival (p = 0.018) than luminal breast cancer patients negative for interleukin-13 receptor alpha 2 expression. However, no association between interleukin-13 receptor alpha 2 expression and clinical outcome was observed in HER2-positive and triple-negative subgroups (p = 0.574 and p = 0.936, respectively). Multivariate analysis showed interleukin-13 receptor alpha 2 expression was an independent poor prognostic factor for luminal breast cancer (p = 0.03). This study shows interleukin-13 receptor alpha 2 expression could be a useful prognostic marker for selecting patients with luminal breast cancer likely to follow a clinically aggressive course despite receiving systemic therapy.

1 January 2023 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
MKMinchong Kim
Minchong Kim
SKSun Young Kwon
Sun Young Kwon
JCJung Eun Choi
Jung Eun Choi
SKSu Hwan Kang
Su Hwan Kang
YBYoung Kyung Bae
Young Kyung Bae
Kim MC, et al. J Breast Cancer. 2023 Apr;26:e19. https://doi.org/10.4048/jbc.2023.26.e19

1 January 2023 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
SBSoo Yeon Baek
Soo Yeon Baek
HKHong-Kyu Kim
Hong-Kyu Kim
SPSeho Park
Seho Park
JYJonghan Yu
Jonghan Yu
MLMin Hyuk Lee
Min Hyuk Lee
HKHee Jeong Kim
Hee Jeong Kim
Baek SY, et al. J Breast Cancer. 2023 Oct;26:e44. https://doi.org/10.4048/jbc.2023.26.e44

6 September 2022 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
BKBong Kyun Kim
Bong Kyun Kim
JCJung Eun Choi
Jung Eun Choi
HYHyun Jo Youn
Hyun Jo Youn
HPHyung Seok Park
Hyung Seok Park
DKDooreh Kim
Dooreh Kim
KSKorean Breast Cancer Society
Korean Breast Cancer Society
Kim BK, et al. Ann Surg Treat Res. 2022 Sep;103(3):119-128. https://doi.org/10.4174/astr.2022.103.3.119